Blogs (8)

Izalontamab (SI-B001) is a Bispecific Anti-EGFR/HER3 mAb for Cancer Research

Izalontamab is an EGFR/HER3 Bi-specific monoclonal antibody. Besides, Izalontamab has the potential for the research of cancer.
Ruxolitinib (INCB018424) is a Selective JAK1/2 Inhibitor for Cancer Research

Ruxolitinib is an orally-active JAK1/2 inhibitor. Ruxolitinib has the potential for the research of myeloproliferative neoplasm (MPN).
Ferristatin (NSC306711) is a Potent Iron Transport Inhibitor and Promotes Transferrin Receptor Degradation

Ferristatin is a potent iron transport inhibitor and shows antiviral potency and anti-MTase (methyltransferase) activity.
GN25 is a Specific p53-Snail Binding Inhibitor with Antitumor Effects

GN25 is a specific inhibitor of p53-Snail binding and shows anti-tumor effect against K-Ras-mutated cancer.
Etrolizumab is a Gut-selective, Anti-β7 Integrin McAb for Inflammatory Bowel Disease (IBD) Research

Etrolizumab is a gut-selective, anti-β7 integrin monoclonal antibody and has the potential for the research of inflammatory bowel disease.
DC-S239 is a Selective SET7 Inhibitor With Anti-Cancer Activity

DC-S239 is a potent and selective SET7 Inhibitor, and DC-S239 shows antiproliferative activity for some cancer cells.
Namodenoson (CF-102) is a Selective A3 Adenosine Receptor (A3AR) Agonist

Namodenoson (CF-102) is a selective A3 adenosine receptor (A3AR) agonist.
Splitomicin is a cell-permeable, potent SIR2 Inhibitor

Splitomicin is a cell-permeable, potent inhibitor of SIR2. Splitomicin inhibits the aggregation of human platelets.

Name
Email *

	Sorry, but the email address you supplied was invalid.